ReviewJournal of gastrointestinal oncology2025
Recent advancements in systemic therapy for biliary tract cancers: a literature review.
Review in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Biliary tract cancers (BTCs), including gallbladder cancer and cholangiocarcinoma, represent a rare yet aggressive class of malignancies with limited therapeutic options and poor survival outcomes. BTCs have been traditionally managed with gemcitabine and cisplatin (GC), but this standard of care has shown limited efficacy due to early recurrence, high resistance rates, and molecular heterogeneity. This review comprehensively summarizes the latest developments in systemic therapies for BTCs, emphasizing recent advances in chemotherapy, targeted therapy, immunotherapy, and rational combination regimens. Particular focus is given to molecularly guided treatment strategies and the evolving role of biomarkers in personalizing therapy. Methods: A thorough search of PubMed, EMBASE, Google Scholar, and the Cochrane Library was conducted for literature published from December 2010 to December 2024. Peer-reviewed clinical trials, meta-analyses, and relevant conference abstracts were examined, especially those related to emerging systemic treatments, molecular targets, and ongoing trials. Particular attention was given to dosing strategies and the integration of novel agents in optimizing patient outcomes. Key Content and Findings: Recent breakthroughs in molecular profiling have identified actionable alterations such as Conclusions: Systemic therapy for BTCs is undergoing a transformative shift, driven by precision oncology and immunotherapeutic advances. Personalized treatment guided by molecular characteristics is now central to improving outcomes. Future efforts must prioritize the identification of biomarkers, clarification of resistance mechanisms, and optimization of multimodal treatment strategies to maximize patient benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.